Journal Article

Immunogenicity and Reactogenicity of 2009 Influenza A

Tayra, Angela, Luiz, André M, Timenetsky, Maria do Carmo S. T, Abdala, Edson, Pierrotti, Lígia C, Aikawa, Nádia E, Luna, Expedito, Azevedo, Luiz S, Cardoso, Maria Regina A, Miraglia, João L, Saad, Carla G. S, Kalil, Jorge, Campos, Lúcia Maria A, Raw, Isaias, Viso, Ana T. R, Laurindo, Ieda M. M, Oliveira, Danise S, Hoff, Paulo M, Guedes, José da S, Precioso, Alexander R

2011

Overview

Immunosuppressed individuals present serious morbidity and mortality from influenza, therefore it is important to understand the safety and immunogenicity of influenza vaccination among them. This multicenter cohort study evaluated the immunogenicity and reactogenicity of an inactivated, monovalent, non-adjuvanted pandemic (H1N1) 2009 vaccine among the elderly, HIV-infected, rheumatoid arthritis (RA), cancer, kidney transplant, and juvenile idiopathic arthritis (JIA) patients. Participants were included during routine clinical visits, and vaccinated according to conventional influenza vaccination schedules. Antibody response was measured by the hemagglutination-inhibition assay, before and 21 days after vaccination. 319 patients with cancer, 260 with RA, 256 HIV-infected, 149 elderly individuals, 85 kidney transplant recipients, and 83 with JIA were included. The vaccine was safe among all groups, with an acceptable immunogenicity among the elderly and JIA patients, however new vaccination strategies should be explored to improve the immune response of immunocompromised adult patients. (ClinicalTrials.gov, NCT01218685)

• Publisher: Public Library of Science
• Subject: Arthritis / Elderly / Health aspects / Influenza / Influenza vaccines / Kidney transplantation / Mortality / Patients / Rheumatoid factor / Vaccination